RT Journal Article
SR Electronic
T1 Duration of viral shedding of the Omicron variant in asymptomatic and mild COVID-19 cases from Shanghai, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.08.22283272
DO 10.1101/2022.12.08.22283272
A1 Sun, Weijie
A1 Yang, Naibin
A1 Mao, Yang
A1 Yan, Danying
A1 Song, Qifa
A1 Qian, Guoqing
YR 2022
UL http://medrxiv.org/content/early/2022/12/09/2022.12.08.22283272.abstract
AB Background The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), designated as a variant of concern by the World Health Organization, spreads globally and was confirmed as the cause of the Omicron wave of the coronavirus disease 2019 (COVID-19) pandemic in Shanghai, China. The viral shedding duration of Omicron variants needs to be determined.Methods We retrospectively analyzed 382 patients admitted to a shelter hospital for COVID-19. Of the patients, 8 patients were referred to a designated hospital, 100 were infected asymptomatic patients, and 274 patients had mild COVID-19.Results The vaccination rates (including fully and boosted) in the asymptomatic and mild COVID-19 patients were 92.00% and 94.16%, respectively. Majority of the studied population showed a first reverse transcription-polymerase chain reaction cycle threshold (Ct) value of 20. For 2565 nasopharyngeal swabs from close or sub-close contacts, the Ct value gradually increased to 35 for 8 days, and the median duration of viral shedding time was 10 days after the first positive detection of the SARS-CoV-2 nuclei acid.Conclusions Quantitative viral RNA load assays in COVID-19 (BA.2.2.1) close or sub-closed contacts could be used to prevent transmissions and control precautions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Zhejiang Provincial Natural Science Foundation of China (grant number Y23H190011), the Key Program of Natural Science Foundation of Ningbo (grant number 202003N4019), and Ningbo City COVID-19 Epidemic Prevention and Control Project (grant number 202002N7033).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was conducted at the Cixi Dapengshan Shelter Hospital (managed by Ningbo First Hospital, University of Ningbo), and this study was approved by the Ethics Committee of Ningbo First Hospital (approval No. 2022RS065). Written informed consent from patients was waived because this was a retrospective study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2COVID-19Coronavirus disease 2019RT-PCRReverse Transcription-Polymerase Chain ReactionCtCycle thresholdCDCCenter for Disease Control and PreventionCTComputed TomographyVOCVariants of Concern